Apellis Pharmaceuticals (APLS) Price & Analysis

Compare

955 Followers

APLS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$16.10 - $41.94

Previous CloseN/A

Volume215.04K

Average Volume (3M)2.75M

Market Cap

$3.53B

Enterprise Value$2.28B

Total Cash (Recent Filing)$371.47M

Total Debt (Recent Filing)$469.77M

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Nov 10, 2025

EPS Estimate

1.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding126,289,910

10 Day Avg. Volume2,539,498

30 Day Avg. Volume2,745,997

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)17.30

Price to Sales (P/S)5.06

P/FCF Ratio-44.79

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue3.02

Enterprise Value/Gross Profit3.61

Enterprise Value/Ebitda-12.78

Forecast

1Y Price Target

$37.19

Price Target Upside31.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say

Market OpportunitiesEmpaveli label expansion into C3G and IC-MPGN per FDA approval is allowing investors to focus on new opportunities.

Product EfficacyEmpaveli's position as the sole C3-targeted therapy and rapid onset of action in preserving renal function is highlighted.

Revenue PotentialA strong launch could provide upside to the current estimate for Empaveli revenues in 2026.

Bears Say

Funding IssuesIssues remain for the patient copay assistance program funding, which is still keeping some patients on the sidelines.

Market ChallengesThe launch could be impacted by the fragmented market, underdiagnosis, and issues with payor access.

Revenue ShortfallAPLS reported total revenue of $178M, below the expected $195M and FactSet consensus of $187M, driven by a $13M headwind in the GA franchise due to higher sample vial usage.

Apellis Pharmaceuticals News

Short Report: Kohls, Krispy Kreme shorts cover as meme stock fever breaks

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

13d ago

KSS

PGY

Apellis price target raised to $37 from $35 at JPMorgan

JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating...

24d ago

APLS

Apellis price target raised to $40 from $39 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Apellis (APLS) to $40 from $39 and keeps an Overweight...

27d ago

APLS

Apellis price target lowered to $50 from $52 at Raymond James

Raymond James lowered the firm’s price target on Apellis (APLS) to $50 from $52 and keeps an Outperform...

27d ago

APLS

Apellis price target raised to $52 from $46 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Apellis (APLS) to $52 from $46 and keeps...

27d ago

APLS

Apellis price target raised to $26 from $24 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Apellis (APLS) to $26 from $24 and...

28d ago

APLS

3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

28d ago

APLS

Apellis reports Q2 EPS (33c), consensus (47c)

Reports Q2 revenue $178.494M, consensus $188.65M. “We are incredibly proud of the recent FDA approval of EMPAVELI in...

28d ago

APLS

Apellis price target raised to $22 from $20 at Scotiabank

Scotiabank raised the firm’s price target on Apellis (APLS) to $22 from $20 and keeps a Sector Perform...

29d ago

APLS

Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Apellis Pharmaceuticals. The associated...

21d ago

APLS

Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook

Apellis Pharmaceuticals (($APLS)) has held its Q2 earnings call. Read on for the main highlights of the call....

22d ago

APLS

Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals

Analyst Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Apellis Pharmaceuticals and increased the...

27d ago

APLS

Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion

Morgan Stanley analyst Judah Frommer has maintained their neutral stance on APLS stock, giving a Hold rating yesterday....

27d ago

APLS

Apellis Pharmaceuticals Reports Q2 2025 Earnings

Apellis Pharmaceuticals ( ($APLS) ) has released its Q2 earnings. Here is a breakdown of the information Apellis...

27d ago

APLS

APLS FAQ

What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?

Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $41.94 in the past 12 months.

What is Apellis Pharmaceuticals Inc’s market cap?

Apellis Pharmaceuticals Inc’s market cap is $3.53B.

When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?

Apellis Pharmaceuticals Inc’s upcoming earnings report date is Nov 10, 2025 which is in 74 days.

How were Apellis Pharmaceuticals Inc’s earnings last quarter?

Apellis Pharmaceuticals Inc released its earnings results on Jul 31, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.465 by $0.135.

Is Apellis Pharmaceuticals Inc overvalued?

According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apellis Pharmaceuticals Inc pay dividends?

Apellis Pharmaceuticals Inc does not currently pay dividends.

What is Apellis Pharmaceuticals Inc’s EPS estimate?

Apellis Pharmaceuticals Inc’s EPS estimate is 1.59.

How many shares outstanding does Apellis Pharmaceuticals Inc have?

Apellis Pharmaceuticals Inc has 126,289,910 shares outstanding.

What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?

Apellis Pharmaceuticals Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.465. Following the earnings report the stock price went up 17.579%.

Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in APLS

Apellis Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-108.49%

Trailing 12-Months

Asset Growth

-9.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals (APLS) Earnings & Revenues

Historic Earnings Reports

APLS Company Deck

APLS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive trajectory for Apellis with significant achievements such as FDA approval for EMPAVELI's expanded label, continued market leadership of SYFOVRE, and strong financial positioning. However, challenges such as high free goods usage affecting revenue and ongoing funding shortages for patient assistance programs present areas of concern.View all APLS earnings summaries

APLS Stock 12 Month Forecast

Average Price Target

$37.19

▲(31.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","61":"$61","27.25":"$27.3","38.5":"$38.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,27.25,38.5,49.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,25.799999999999997,28.65,31.5,34.349999999999994,37.199999999999996,40.05,42.89999999999999,45.75,48.599999999999994,51.449999999999996,54.3,57.14999999999999,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,24.045384615384613,25.14076923076923,26.236153846153844,27.33153846153846,28.426923076923075,29.52230769230769,30.617692307692305,31.71307692307692,32.808461538461536,33.90384615384615,34.99923076923076,36.09461538461538,{"y":37.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,22.646153846153844,22.342307692307692,22.038461538461537,21.734615384615385,21.43076923076923,21.126923076923077,20.823076923076922,20.51923076923077,20.215384615384615,19.911538461538463,19.607692307692307,19.303846153846155,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >